Longevity

Ageing is the biological process most people hold an opinion about and nobody has an agreed way to measure. That absence is what makes claims here so hard to sort: they tend to be technically true and to answer a different question from the one that was asked. Sorting them takes arithmetic rather than biology — which deaths is this number made of, did the intervention lower the mortality curve or change its rate of rise, and what quantity stood in for the outcome nobody waited long enough to observe. Three questions, learnable in an afternoon, usable for a lifetime, and requiring no more cell biology than a reader already has. The record assembled here is unusually candid about where it runs out: two primate studies of the same intervention disagree inside it, the documented age of the longest-lived person has been publicly challenged inside it, and the field's most visible biomarker is entered as a correlate rather than a measure.

• The missing surrogate endpoint for ageingphysical criterionThe Journey's protagonist is a thing that does not exist. Every earlier chapter describes a substitute measurement; this is the record that says why substitutes are all there is.
• The Gompertz mortality lawmodelThe instrument the whole Journey uses. Without the distinction between the height of the mortality curve and its rate of rise, nothing that follows can be sorted into public health and ageing.
• The rise in life expectancy at birthphenomenonThe number the reader arrives holding, and the one this Journey spends two chapters taking apart before it will let anyone use it.
• Sanitation and water treatmenttechnology systemThe largest identified contributor in the corpus, and the least biological. It carries the Journey's argument that the gains were infrastructural rather than medical.
• Maximum human lifespanphysical thresholdThe upper edge the compression of mortality squares up against. Its job here is to be the quantity that did not move while everything else did.
• Jeanne CalmentpersonA single life doing the work of a dataset. She is featured not as a record-holder but as the best-documented case in the field, which is exactly why the argument about her documentation is so instructive.
• Blue ZonesregionThe popular half of the subject, kept in rather than dismissed, because the objection to it is the same objection the ceiling chapter has just made at the scale of one person.
• Model organism lifespan researchresearch programmeWhere ageing genuinely is modifiable. The Journey needs this to be impressive, because the translation problem is only interesting if the preclinical result is real.

Showing 8 of 16 featured records. Atlas does not choose which of the rest matter.

• The oldest documented individual and the longest-lived reported populations are challenged by the same instrument, and it is not a biological one. An unverifiable age in one person and an unverifiable centenarian density in one region are a single problem — birth registration — met at two scales. A reader who accepts the objection at one scale has already accepted it at the other.

  Maximum human lifespan · Blue Zones

• The largest identified contributor to how long people live was legislated into existence by a man who held the wrong theory of disease throughout. Right prescription, wrong mechanism — and the prescription worked anyway, which is an uncomfortable data point for anyone who believes interventions must be understood before they can be trusted.

  Sanitation and water treatment · The rise in life expectancy at birth

• The only randomised controlled trial of sustained human restriction had to borrow its outcome from an unvalidated candidate surrogate, because there was nothing else to measure. The circularity is worth sitting with: validating the clock requires a trial with a clinical endpoint, and the trial that might have supplied one used the clock instead.

  CALERIE (Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy) · Epigenetic clocks · The missing surrogate endpoint for ageing

• The law that supplies this Journey's central test is the same law a disputed finding contradicts at the far end of the age range. The instrument and the anomaly are the same curve, and whether the anomaly is real depends on records rather than on biology — which is the Journey's recurring shape appearing inside its own method.

  The late-life mortality plateau · The Gompertz mortality law

• Is the late-life mortality plateau real, or an artefact of overstated ages?

  One published position infers a limit from a maximum reported age at death that stopped rising in the mid-1990s; another reports, from individually validated records, a death hazard that flattens after about 105. The corpus records both and notes they are not reconcilable from the data currently available, because the disagreement is about the reliability of ages at the extreme tail rather than about a biological process.

• How much of the blue-zone effect survives the record-quality objection?

  The critique holds that reported hotspots track late or absent birth registration, pension incentives and low income. The corpus records it as preprint material whose peer-review status it does not establish, and it also records that the original Sardinian sex-ratio finding has not been explained away. Genuinely open, and the Journey declines to close it in either direction.

• Why did the two long-running primate restriction studies reach opposite conclusions?

  One reported reduced age-related mortality, the other no significant survival benefit. The reconciliation offered — diet composition, age at onset, and how the control animals were fed — is itself an interpretation, and if the controls in one study were effectively overfed then that trial compared restriction against overfeeding rather than against a healthy baseline. That is a different experiment, and the corpus does not choose between the readings.

• Can any biomarker be validated as a surrogate for human ageing?

  No trial has yet moved a clock and a clinical endpoint together in the same population, which is what validation would require. The corpus raises the further possibility that ageing is too heterogeneous across organ systems for any single number to serve — in which case the trials this field needs may not be affordable at all. This is the open question the whole Journey converges on.

• Is the gap between how long people live and how long they live well stable, widening or narrowing?

  The compression-of-morbidity proposal predicted the gap would close and the paired global figures have not confirmed it. But the answer depends heavily on how disability is weighted, and the corpus records that the methodology has changed across editions in ways that make long comparisons unreliable. The honest position is that the trend cannot be read confidently from the published series.

• How does the historical mortality decline apportion between water, nutrition, housing, income and infection control?

  The strongest single estimate attributes roughly half of one country's urban decline in one period to filtration and chlorination. The corpus is explicit that this does not transfer automatically to other places or times, and that the apportionment is contested. The pre-1900 global series is in any case a reconstruction from fragmentary records with wide bounds.

• Does the accumulation of senescent cells cause human ageing, result from it, or both?

  Unsettled, and currently hard to attack directly: the corpus records that no assay reliably counts senescent cells in a living person. The drugs aimed at these cells therefore reached patients before the question their existence poses could be posed properly.

Two things are true and they are not the same thing: far fewer people die young than once did, and nobody has shown that any human being ages more slowly than a human being did in 1825. The first was bought — with drainage, immunisation and antibiotics — and it is held rather than owned, which is why it has run backwards more than once, a decade of gains erased inside a single pandemic. The second has been paid for as well, and it is worth naming who paid. Two long-running primate studies kept monkeys on restricted diets and reached opposite conclusions. A cohort of volunteers ate less for two years, and the trial that watched them could say nothing at all about how long they lived. That is the standing charge for an absent endpoint, and it falls on the subjects of every study obliged to proceed without one.

This is unfinished in the world, not only in the telling.

• How these connect →What is related to what, and on what evidence? · central to this Journey
• When they happened →What happened, in what order, and what changed?
• What has no place →What in this subject has no location at all?
• Ask the world another question →What else is in the corpus about this? · Dynamic, and nothing it answers becomes canonical

• Industrial Revolutioncausal consequence · crosses into HistoryThe same sanitary report appears in both Journeys and is read in opposite directions: here as the origin of the largest gain in human survival, there as the accounting of what urban growth cost the people inside it. A reader who has just credited municipal plumbing should see the towns that made it necessary.
• Evolution of Lifeshared system · crosses into NatureThe nematode whose lifespan a single gene doubles is on the other Journey a point on a much longer record. Asking why a two-week organism can be reprogrammed and a decades-long one cannot is a question about lineage, and that Journey is where lineage is the subject.
• What AI Changesrepeated human patternBoth Journeys turn on the same failure: a field that cannot measure the thing it claims to improve adopts a proxy, and the proxy quietly becomes the goal. A reader who has just watched an unvalidated clock stand in for a lifetime will recognise the move immediately.
• Future Citiesinstitutional legacyThe single largest contributor in this Journey is a piece of municipal infrastructure that most residents never think about. That is the other Journey's entire subject, and it makes the case that the next gains in human survival may also be civic rather than clinical.

• Think this through in Studio →What else is currently judged by a proxy that has never been shown to move together with the outcome it stands for?

Ask the world another question. Dynamic keeps this Journey as its context and never changes what is written above.